Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. SPY
2. META
3. USO
4. MSFT
5. MU
6. COST
7. IONS
8. AVAV
9. SKHY
10. CG

Go back to Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)
AGIOS PHARM (NASDAQ: AGIO) Delayed: 42.79 +0.03 (0.07%)
Previous Close $42.76    52 Week High $71.49 
Open $42.58    52 Week Low $33.50 
Day High $43.17    P/E N/A 
Day Low $41.96    EPS $-1.18 
Volume 519,939